LifeMD Statistics
Total Valuation
LifeMD has a market cap or net worth of $148.46 million. The enterprise value is $129.33 million.
| Market Cap | 148.46M |
| Enterprise Value | 129.33M |
Important Dates
The last earnings date was Wednesday, August 5, 2026, after market close.
| Earnings Date | Aug 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LifeMD has 48.20 million shares outstanding. The number of shares has increased by 9.50% in one year.
| Current Share Class | 48.20M |
| Shares Outstanding | 48.20M |
| Shares Change (YoY) | +9.50% |
| Shares Change (QoQ) | +0.96% |
| Owned by Insiders (%) | 14.19% |
| Owned by Institutions (%) | 45.31% |
| Float | 39.66M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 84.83 |
| PS Ratio | 0.77 |
| Forward PS | 0.66 |
| PB Ratio | 18.49 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.68 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.90, with a Debt / Equity ratio of 0.76.
| Current Ratio | 0.90 |
| Quick Ratio | 0.78 |
| Debt / Equity | 0.76 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -85.40 |
Financial Efficiency
Return on equity (ROE) is -515.90% and return on invested capital (ROIC) is -69.33%.
| Return on Equity (ROE) | -515.90% |
| Return on Assets (ROA) | -18.92% |
| Return on Invested Capital (ROIC) | -69.33% |
| Return on Capital Employed (ROCE) | -152.06% |
| Weighted Average Cost of Capital (WACC) | 14.98% |
| Revenue Per Employee | $544,297 |
| Profits Per Employee | -$8,254 |
| Employee Count | 352 |
| Asset Turnover | 2.87 |
| Inventory Turnover | 7.72 |
Taxes
In the past 12 months, LifeMD has paid $45,721 in taxes.
| Income Tax | 45,721 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -49.51% in the last 52 weeks. The beta is 2.04, so LifeMD's price volatility has been higher than the market average.
| Beta (5Y) | 2.04 |
| 52-Week Price Change | -49.51% |
| 50-Day Moving Average | 3.80 |
| 200-Day Moving Average | 3.85 |
| Relative Strength Index (RSI) | 36.58 |
| Average Volume (20 Days) | 687,168 |
Short Selling Information
The latest short interest is 6.95 million, so 14.41% of the outstanding shares have been sold short.
| Short Interest | 6.95M |
| Short Previous Month | 7.57M |
| Short % of Shares Out | 14.41% |
| Short % of Float | 17.52% |
| Short Ratio (days to cover) | 6.58 |
Income Statement
In the last 12 months, LifeMD had revenue of $191.59 million and -$2.91 million in losses. Loss per share was -$0.09.
| Revenue | 191.59M |
| Gross Profit | 167.64M |
| Operating Income | -20.20M |
| Pretax Income | -21.49M |
| Net Income | -2.91M |
| EBITDA | -18.96M |
| EBIT | -20.20M |
| Loss Per Share | -$0.09 |
Balance Sheet
The company has $25.14 million in cash and $6.02 million in debt, with a net cash position of $19.12 million or $0.40 per share.
| Cash & Cash Equivalents | 25.14M |
| Total Debt | 6.02M |
| Net Cash | 19.12M |
| Net Cash Per Share | $0.40 |
| Equity (Book Value) | 7.97M |
| Book Value Per Share | 0.17 |
| Working Capital | -4.52M |
Cash Flow
In the last 12 months, operating cash flow was -$6.69 million and capital expenditures -$1.15 million, giving a free cash flow of -$7.84 million.
| Operating Cash Flow | -6.69M |
| Capital Expenditures | -1.15M |
| Depreciation & Amortization | 1.24M |
| Net Borrowing | -16.67M |
| Free Cash Flow | -7.84M |
| FCF Per Share | -$0.16 |
Margins
Gross margin is 87.50%, with operating and profit margins of -10.54% and 0.10%.
| Gross Margin | 87.50% |
| Operating Margin | -10.54% |
| Pretax Margin | -11.22% |
| Profit Margin | 0.10% |
| EBITDA Margin | -9.89% |
| EBIT Margin | -10.54% |
| FCF Margin | n/a |
Dividends & Yields
LifeMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.50% |
| Shareholder Yield | -9.50% |
| Earnings Yield | -1.96% |
| FCF Yield | -5.28% |
Analyst Forecast
The average price target for LifeMD is $8.13, which is 163.96% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $8.13 |
| Price Target Difference | 163.96% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (3Y) | 13.04% |
| EPS Growth Forecast (3Y) | 56.36% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on October 14, 2020. It was a reverse split with a ratio of 1:5.
| Last Split Date | Oct 14, 2020 |
| Split Type | Reverse |
| Split Ratio | 1:5 |
Scores
LifeMD has an Altman Z-Score of -0.87 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.87 |
| Piotroski F-Score | 3 |